Product Description
monoclonal antibodies for SARS-CoV-2 infection (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479899/)
Mechanisms of Action: Mpro Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BeiGene
Company Location: GRAND CAYMAN E9 KY1-1108
Company CEO: John V. Oyler
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04669262 |
BGB-DXP604-101 | P1 |
Completed |
Healthy Volunteers |
2021-05-21 |
12% |
2024-03-16 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|